Minority Representation Needs Improvement in Cancer Trials
An analysis of enrollment incidence ratios revealed that Black and Hispanic patients were both significantly underrepresented in U.S. trials.
Related Articles
RNU Versus Kidney-Sparing Surgery for High-Grade UTUC | GU Oncology Now
Helen Gao highlights her comparative outcomes analysis of RNU and kidney-sparing surgery in the treatment of high-grade UTUC.
Daniel Spratt, MD – Offering Mentorship, Purpose for Aspiring Radiation Oncologists | GU Oncology Now
Dr. Spratt ponders the evolving integration of RT with systemic treatments, challenges in counseling patients, and more.
FDA Approves IL-15 Receptor Agonist for BCG-Unresponsive NMIBC | GU Oncology Now
The FDA approved Anktiva for patients with BCG-unresponsive NMIBC with CIS with or without papillary tumors.
Evaluating Gemcitabine, Docetaxel Versus Bacillus Calmette-Guérin in Patients With UTUC | GU Oncology Now
The only guideline-recommended endoluminal treatment option for patients with HG UTUC is bacillus Calmette-Guérin.
Molecular Testing for aUC: Navigating FGFR-Targeted Therapy | GU Oncology Now
Dr. Joshi contextualizes the THOR study within the treatment landscape for FGFR2/3-altered advanced urothelial carcinoma.
The Uromigos Episode 310: Dosing and Duration of Drugs From a Cost Perspective | GU Oncology Now
Daniel Goldstein returns to the podcast to discuss dosing issues and dosing changes in drugs such as nivolumab and pembrolizumab, as well as other immune…
Recent Updates in #Molecular Imaging for #ProstateCancer #Clinical Trials #cancer #news
Gary Ulaner, MD, PhD, FSNMMI, FACNM, of Hoag Family Cancer Institute, highlights 2 new clinical trials for prostate cancer staging and treatment: MIRROR and …
NSGCTs With Teratoma Negatively Affects Patients in Good, Intermediate Prognosis Groups | GU Oncology Now
Researchers used the IGCCCG Update Consortium database to compare the survival probabilities of patients with metastatic testicular GCTs with or without teratoma.
Leonard Gomella – A Decades-Long Commitment to Advancing Urology | GU Oncology Now
Dr. Gomella tells his journey to becoming a urologist, the importance of multidisciplinary care, and challenges in the field.
ARON-1: IO Versus TKI for Papillary Renal Cell Carcinoma | GU Oncology Now
The ARON-1 study investigated the efficacy of first-line treatment with TKIs versus IO-based combinations in patients with pRCC, the most common histological subtype of nccRCC.